Feature article: 2024 pharma statistics
An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024. The year was characterised by 9.2% underlying (ex-COVID-19) growth. Much of the growth was driven by recently launched anti-obesity drugs and oncology drugs. Both Eli Lilly and Novo Nordisk have entered the global top 10 ranking for the first time in their history.

01 Apr 2025
Hardman & Co Monthly: April 2025

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Hardman & Co Monthly: April 2025
Volta Finance Limited (VTA:LON), 685 | Real Estate Credit Investments Limited (RECI:LON), 126 | NB Private Equity Partners Limited Class A (NBPE:LON), 1,502 | ICG Enterprise Trust PLC GBP (ICGT:LON), 1,502 | Arbuthnot Banking Group PLC (ARBB:LON), 930 | accesso Technology Group Plc (ACSO:LON), 428
- Published:
01 Apr 2025 -
Author:
Martin Hall | Mark Thomas | Richard Jeans -
Pages:
27 -
Feature article: 2024 pharma statistics
An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024. The year was characterised by 9.2% underlying (ex-COVID-19) growth. Much of the growth was driven by recently launched anti-obesity drugs and oncology drugs. Both Eli Lilly and Novo Nordisk have entered the global top 10 ranking for the first time in their history.